# DF/HCC Kidney Cancer SPORE Tissue, Acquisition, Pathology and Clinical Data Core 2

> **NIH NIH P50** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2020 · $626,676

## Abstract

Summary:
The first and foremost goal of the Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core is to maintain
and expand the existing repository for specimens, including tissues, blood and urine from patients with kidney
tumors that have given consent to link their samples to clinical data. Included in this component are the
collection, freezing, and storage of fresh samples of kidney cancer and paired non-tumor tissue; the collection,
processing and storage of blood and urine; the identification and provision of samples of fixed tissues,
including construction of tissue microarrays (TMAs) from biopsy and nephrectomy samples obtained from
patients who have consented to allow analysis of these tissues. The caTissue system, which is the NCI
caBIG's biorepository tool for biospecimen inventory management, is currently used to track specimens
through every step of the requesting, shipping, and receiving process through the use of barcode technology.
Importantly, the TAPCD Core will continue to maintain a database of clinical data (CRIS) on all consenting
RCC patients. The value of the database is enhanced by the use of standardized pathology review procedures
and data collection procedures. The database and specimen tracking system provide an informatics link
among the participating Dana-Farber/Harvard Cancer Center (DF/HCC) hospitals, including the Dana-Farber
Cancer Institute and Brigham and Women’s Hospital (DFCI/BWH), the Beth Israel Deaconess Medical Center
(BIDMC), and the Massachusetts General Hospital (MGH). This allows seamless sharing of specimen
resources, linked to clinical outcome data, behind a secure data management system that is available to
SPORE investigators at all participating institutions. The protection of patient confidentiality is guarded
throughout the whole process, from specimen collection to use in research projects. The Biostatistics and
Bioinformatics Core is and will continue to be responsible for assisting in the data analysis, data auditing and
quality control.
Finally, TAPCD Core has provided and will continue to provide SPORE investigators a variety of services
critical to successful molecular analysis of human kidney tumors as well as animal models. These services
include: histopathologic review and quality control analysis of all tumor samples utilized in experimental
studies; macrodissection of frozen tissue samples and slide microdissection of paraffin-embedded or frozen
tissues to ensure high neoplastic cellularity for samples utilized in experimental studies; laser capture
microdissection (LCM) to provide ultra-pure tumor samples; performance of routine immunohistochemistry
(IHC) and multiparametric immunofluorescence (IF) stains on human kidney cancers (TMAs or whole tissue
sections); optimization and validation of antibodies to known and novel proteins for use in IHC and IF; analysis
of a broad range of IHC and multiplex IF stains using computer-assisted image analysis; development of novel
RCC ...

## Key facts

- **NIH application ID:** 10024140
- **Project number:** 2P50CA101942-16
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** RUPAL S BHATT
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $626,676
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10024140

## Citation

> US National Institutes of Health, RePORTER application 10024140, DF/HCC Kidney Cancer SPORE Tissue, Acquisition, Pathology and Clinical Data Core 2 (2P50CA101942-16). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/10024140. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*